A Phase 3 interventional study of Aripiprazole in Tourette's Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 80 sites in 10 countries. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2021-10-07.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing aripiprazole in Tourette Syndrome — none open to participants now, none under way, none of them phase 3. Aripiprazole · Tourette Syndrome.
Among the 10 studies testing aripiprazole in Tourette Syndrome, this one has the largest enrollment, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 4th registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →None of the 10 studies testing aripiprazole in Tourette Syndrome is open now. The open studies under Tourette Syndrome, anywhere →
Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 7 Years to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2011.
This study's enrollment of 170 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 97 across the 10 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 10 have an industry lead sponsor. The 5 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 9 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing aripiprazole in Tourette Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of the current trial is to obtain long term efficacy, safety and tolerability data of once weekly aripiprazole in children and adolescents with Tourette's Disorder.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral aripiprazole tablets once weekly (QW) with a titrated dose starting from 52.5 milligram (mg), on Day 1 and increasing to 77.5 mg and 110 mg for the remainder of the trial (Up to Week 52), the dose could be adjusted between these 3 dose levels as determined by investigator's discretion based on safety and tolerability.
Drug: Aripiprazole
Aripiprazole tablets orally once daily.
Also known as: ABILIFY
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Severe TEAEs and TEAEs Leading Treatment Discontinuation
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. Treatment emergent adverse events (TEAE) are adverse events occurring after the onset of study drug administration.
Time frame: From signing of the informed consent up to 30 days after the last dose (Up to Week 52)
Number of Participants With Clinically Significant Changes in Laboratory Parameter Values
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance.
Time frame: Baseline to Week 52
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Values
Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported.
Time frame: Baseline to Week 52
Number of Participants With Emergence of Suicidal Ideation, TEAEs Related to Suicide and Suicidality and Suicide Ideation From the Potential Suicide Events Recorded on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.
Time frame: Baseline to Week 52
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score
The AIMS Scale is an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10) are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Body Mass Index (BMI)
The BMI kilogram/meter square (i.e. kg/m\^2) was calculated from the Baseline height and the weight at the current visit using one of the following formulae, as appropriate: Weight (kg) divided by \[Height (meters)\]\^2.
Time frame: Baseline and Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs assessments included orthostatic (supine and standing) blood pressure (BP) measured as millimeter of mercury \[mmHg\]), heart rate, (measured in beats per minute \[bpm\]), body weight (measured in kilograms \[kg\]) and body temperature. Incidence of clinically relevant abnormal values in heart rate, systolic and diastolic blood pressure and weight were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant has been supine for at least 5 minutes and again after the participant has been standing for approximately 2 minutes, but not more than 3 minutes.
Time frame: Baseline to Week 52
Mean Change From Baseline in Simpson Angus Scale (SAS) Score
The SAS is a rating scale used to measure Extrapyramidal symptoms (EPS). The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32, 40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score
The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Average Score of Attention-Deficit Disorder/Attention-Deficit Hyperactivity Disorder (ADD/ADHD) Sub-scale of the Swanson, Nolan and Pelham-IV (SNAP-IV)
The SNAP-IV, ADHD Inattention subscale contains 19 items, items 1 to 9 measure inattention, items 11 to 19 measure hyperactivity/impulsivity, and item 10 for inattention domain that scores the intensity of each item during the last seven days on a 0 to 3 scale (0=not at all, 1=just a little, 2=pretty much, 3=very much). The lowest possible score is 0; highest is 57. The negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) Total Score
The CY-BOCS is used to assess characteristics of obsession and compulsion for the week prior to the interview. Nineteen items are rated in the CY-BOCS, but the total score is the sum of only items 1 to 10 (excluding items 1b and 6b). The obsession and compulsion subtotals are the sums of items 1 to 5 (excluding 1b) and 6 to 10 (excluding 6b), respectively. A missing value for any CY-BOCS item scale could result in a missing total score or obsession and compulsion subtotals of which the item scale is a component. At baseline, the full CY-BOCS interview is conducted. At all post-baseline time points, the "Questions on Obsessions" (items 1 to 5) and "Questions on Compulsions" (items 6 to 10) are reviewed and the target symptoms identified at baseline are the primary focus for rating severity. CY-BOCS total score could range from 0 to 40. Higher scores indicate worse outcome. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Children's Depression Rating Scale Revised (CDRS-R) Total Score
The CDRS-R is composed of 17 interviewer-rated symptom areas: impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas. A missing value for any CDRS-R item scale or a not rated item scale (indicated by the value of 0) could result in a missing total score. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Pediatric Anxiety Rating Scale (PARS) Total Severity Score
The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. Information is elicited from the child and parent(s) and the rater then combines information from all informants using his/her best judgment. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS rating is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score is the sum of items 2, 3, 5, 6, and 7. The total severity score ranges from 0 to 25, with 25 being the worst. Codes "8" (Not applicable) and "9" (Does not know) are not included in the summation (ie, equivalent to a score of 0 in the summation). A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Body Weight
Time frame: Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Waist Circumference
Waist circumference was recorded before a participant's meal and at approximately the same time at each visit. Measurement was accomplished by locating the upper hip bone and the top of the right iliac crest and placing the measuring tape in a horizontal plane around the abdomen at the level of the crest. Before reading the tape measure, the assessor assured that the tape was snug, but did not compress the skin, and is parallel to the floor. The measurement was made at the end of a normal exhalation.
Time frame: Baseline to Weeks 12, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Yale Global Tic Severity Scale (YGTSS) Total Tic Score
The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (A negative change from Baseline indicates improvement).
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Clinical Global Impression for Tourette's Syndrome (CGI-TS) Severity of Illness Score
The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Mean Change From Baseline in Total YGTSS Score
The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A negative change in Total YGTSS score from baseline represents an improvement in symptoms.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Response Rates
Response rates - clinical response was defined as percentage of participants \>25% improvement from Baseline to endpoint in YGTSS TTS OR a CGI-TS change score of 1 \[very much improved\] or 2 \[much improved\] at endpoint. The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100) with higher score representing severe symptoms.
Time frame: Baseline and Weeks 4, 8, 12, 16, 20, 24, 32,40, 52; Last Visit (Week 52 or early termination Visit before Week 52)
Treatment Discontinuation Rates
Treatment discontinuation rate was calculated as the percentage of participants who discontinued treatment.
Time frame: Up to Week 53
Mean Change From Baseline in Gilles de la Tourette Quality of Life (GTS-QOL) Overall Score
The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.
Time frame: Baseline and Weeks 4, 24, 52 and Last Visit (Week 52 or early termination Visit before Week 52)
A total of 170 participants were screened and enrolled. 114 participants were enrolled from study 31-10-272 (NCT01418339) and 56 participants were enrolled from study 31-10-273 (NCT01418352). The participants were recruited at 79 sites in following 10 countries: Bulgaria, Canada, Germany, Hungary, Mexico, Romania, South Korea, Taiwan, Ukraine and the US from 19 October 2011 to 13 March 2014.
| Milestone | Aripiprazole (Once Weekly) |
|---|---|
| Started | 170 |
| Completed | 89 |
| Not completed | 81 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Adverse event | 6 |
| Withdrew: Sponsor discontinued trial site | 43 |
| Withdrew: Subject met withdrawal criteria | 10 |
| Withdrew: Investigator withdrew subject | 2 |
| Withdrew: Subject withdrew consent | 12 |
| Withdrew: Lack of efficacy as determined by the investigator | 3 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a participant enrolled in a clinical trial and which did not necessarily have a causal relationship with the study medication. Treatment emergent adverse events (TEAE) are adverse events occurring after the onset of study drug administration.
| Participants | Aripiprazole (Once Weekly) |
|---|---|
| Participants with Serious TEAEs | 5 |
| Participants with Severe TEAEs | 8 |
| Participants Discontinued Medication due to TEAE's | 6 |
| Participants with TEAEs | 104 |
The laboratory values were one of the parameters to measure the safety and tolerability of individual participants. Participants with potentially clinically significant lab values in serum chemistry, hematology, urinalyses and prolactin tests that were identified based on pre-defined criteria were reported. Any value outside the normal range was flagged for the attention of the investigator who assessed whether or not a flagged value is of clinical significance.
| Participants | Aripiprazole (Once Weekly) |
|---|---|
| Chemistry-Alkaline Phosphatase | 0 |
| Chemistry-Alanine Aminotransferase | 1 |
| Chemistry-Aspartate Aminotransferase | 1 |
| Chemistry-Bilirubin, Total | 4 |
| Chemistry-Calcium | 0 |
| Chemistry-Chloride | 0 |
| Chemistry-Creatine Phosphokinase | 4 |
| Chemistry-Creatinine | 0 |
| Chemistry-Glucose | 1 |
| Chemistry-Glucose, Fasting | 1 |
| Chemistry-HDL Cholesterol, Fasting | 3 |
| Chemistry-Lactic Dehydrogenase | 1 |
| Chemistry-LDL-Cholesterol, Fasting | 2 |
| Chemistry-Potassium | 0 |
| Chemistry-Sodium | 0 |
| Chemistry- Triglycerides, Fasting | 19 |
| Chemistry- Urea Nitrogen | 0 |
| Chemistry-Uric Acid | 0 |
| Urinalysis-Glucose, Urine | 3 |
| Urinalysis-Protein, Urine | 1 |
| Other-Prolactin | 3 |
| Haematology-Eosinophils | 3 |
| Haematology-Hematocrit | 0 |
| Haematology-Hemoglobin | 3 |
| Haematology-Neutrophils | 0 |
| Haematology-Platelet Count | 0 |
| Haematology-White Blood Count | 4 |
Incidence of clinically relevant abnormal ECG values were reported as change from Baseline in heart rate (Tachycardia - ≥15 beats per minute (bpm), Bradycardia ≤15 bpm; Rhythm (Sinus tachycardia ≥15 bpm increase, Sinus bradycardia decrease of ≥15 bpm from Baseline); Presence of - supraventricular premature beat; ventricular premature beat; supraventricular tachycardia; ventricular tachycardia; atrial fibrillation and flutter. Conduction - Presence of primary, secondary or tertiary atrioventricular block, left bundle-branch block, right bundle-branch block, pre-excitation syndrome, other intraventricular conduction blocked QRS ≥0.12 second increase of ≥0.02 second. Acute, subacute or old Infarction, Presence of myocardial ischemia, symmetrical T-wave inversion. Increase in QTc - QTc ≥450 msec ≥10% increase. Any clinically significant change from Baseline assessed by the Investigator are reported.
| participants | Aripiprazole (Once Weekly) |
|---|---|
| Tachycardia | 1 |
| Bradycardia | 0 |
| Sinus Tachycardia | 1 |
| Sinus Bradycardia | 0 |
| Supraventricular Premature Beat | 4 |
| Ventricular Premature Beat | 3 |
| Supraventricular Tachycardia | 0 |
| Ventricular Tachycardia | 0 |
| Atrial Fibrillation | 0 |
| Atrial Flutter | 0 |
| Primary Atrioventricular Block | 0 |
| Secondary Atrioventricular Block | 0 |
| Tertiary Atrioventricular Block | 0 |
| Left Bundle Branch Block | 0 |
| Right Bundle Branch Block | 2 |
| Pre-excitation Syndrome | 0 |
| Other intraventricular conduction block | 0 |
| Acute or Sub-acute Infarction | 0 |
| Old Infarction | 0 |
| Myocardial Ischemia | 0 |
| Symmetrical T-Wave Inversion | 1 |
| QT Interval cCorrected for Heart Rate by Bazett's Formula (QTB) | 3 |
| QT Interval Corrected for Heart Rate by Fredericia's Formula (QTcF) | 0 |
| QT Interval Corrected for Heart Rate by the US Food and Drug (QTcN) | 1 |
Suicidality was defined as reporting at least one occurrence of any suicidal behavior or suicidal ideation. Suicidal behavior was defined as reporting any type of suicidal behaviors (actual attempt, interrupted attempt, aborted attempt, and preparatory acts or behavior). Suicidal ideation was defined as reporting any type of suicidal ideation. The suicidal ideation intensity total score is the sum of intensity scores of 5 items (frequency, duration, controllability, deterrents, and reasons for ideation). The score of each intensity item ranges from 0 (none) to 5 (worst) which leads to the range of the total score from 0 to 25. A missing score of any item resulted in a missing total score. If no suicidal ideation was reported, a score of 0 was given to the intensity scale.
| Participants | Aripiprazole (Once Weekly) |
|---|---|
| Emergence of Suicidal Ideation | 3 |
| TEAEs related to Suicide | 3 |
| Suicidality and Suicidal Ideation | 4 |
The AIMS Scale is an extrapyramidal symptoms (EPS) rating scale. The AIMS is a 12 item scale. The first 10 items e.g. facial and oral movements (items 1-4), extremity movements (items 5 and 6), trunk movements (item 7), investigators global assessment of dyskinesia (items 8 to 10) are rated from 0 to 4 (0=best, 4=worst). Items 11 and 12, related to dental status, have dichotomous responses, 0=no and 1=yes. The AIMS Total Score is the sum of the ratings for the first seven items. The possible total scores are from 0 to 28. A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -0.1 ± 1.3 |
| Change at Week 8 | -0.1 ± 1.6 |
| Change at Week 12 | -0.4 ± 1.7 |
| Change at Week 16 | -0.5 ± 2 |
| Change at Week 20 | -0.5 ± 2 |
| Change at Week 24 | -0.6 ± 2.5 |
| Change at Week 32 | -0.8 ± 2.3 |
| Change at Week 40 | -0.8 ± 2.4 |
| Change at Week 52 | -0.9 ± 2.4 |
| Change at Last Visit (Early Termination Visit Prior to or at Week 52 | -0.8 ± 2.3 |
The BMI kilogram/meter square (i.e. kg/m\^2) was calculated from the Baseline height and the weight at the current visit using one of the following formulae, as appropriate: Weight (kg) divided by \[Height (meters)\]\^2.
| kg/m^2 | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 12 | 0.6 ± 0.9 |
| Change at Week 24 | 0.4 ± 1.5 |
| Change at Week 52 | 0.7 ± 2 |
| Change at Last Visit (Early Termination Visit Prior to or at Week 52 | 0.6 ± 1.8 |
Vital signs assessments included orthostatic (supine and standing) blood pressure (BP) measured as millimeter of mercury \[mmHg\]), heart rate, (measured in beats per minute \[bpm\]), body weight (measured in kilograms \[kg\]) and body temperature. Incidence of clinically relevant abnormal values in heart rate, systolic and diastolic blood pressure and weight were identified based on pre-defined criteria. Orthostatic assessments of blood pressure and heart rate were made after the participant has been supine for at least 5 minutes and again after the participant has been standing for approximately 2 minutes, but not more than 3 minutes.
| Participants | Aripiprazole (Once Weekly) |
|---|---|
| Heart Rate Supine- Increase ≥15 bpm | 1 |
| Heart Rate Supine- Decrease ≥15 bpm | 0 |
| Heart Rate Standing-increase ≥15 bpm | 4 |
| Heart Rate Standing- Decrease ≥15 bpm | 0 |
| Systolic Supine BP- Increase ≥20 mmHg | 0 |
| Systolic Supine BP- Decrease ≥20 mmHg | 1 |
| Systolic Standing BP- Increase ≥20 mmHg | 0 |
| Systolic Standing BP- Decrease ≥20 mmHg | 1 |
| Diastolic Supine BP- Increase ≥15 mmHg | 0 |
| Diastolic Supine BP- Decrease ≥15 mmHg | 0 |
| Diastolic Standing BP- Increase ≥15 mmHg | 1 |
| Diastolic Standing BP- Decrease ≥15 mmHg | 0 |
| Orthostatic Hypotension | 2 |
| Weight-Gain ≥ 7% | 82 |
| Weight-Loss ≥ 7% | 6 |
The SAS is a rating scale used to measure Extrapyramidal symptoms (EPS). The SAS scale consists of a list of 10 symptoms of parkinsonism (gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, head rotation, glabella tap, tremor, salivation, and akathisia), with each item rated from 0 to 4, with 0 being normal and 4 being the worst. The SAS Total score is sum of ratings for all 10 items, with possible Total scores from 0 to 40. A negative change from Baseline indicates improvement.
| score on scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | 0 ± 0.3 |
| Change at Week 8 | 0 ± 0.4 |
| Change at Week 12 | 0 ± 0.3 |
| Change at Week 16 | 0 ± 0.4 |
| Change at Week 20 | 0 ± 0.2 |
| Change at Week 24 | 0 ± 0.5 |
| Change at Week 32 | 0 ± 0.4 |
| Change at Week 40 | 0 ± 0.5 |
| Change at Week 52 | 0 ± 0.5 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | 0 ± 0.4 |
The BARS was an EPS rating scale. The BARS was used to assess the presence and severity of akathisia. This scale consists of 4 items. Only the 4th item, the Global Clinical Assessment of Akathisia, was evaluated in this trial. This item is rated on a 6 point scale, with 0 being best (absent) and 5 being worst (severe akathisia). A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | 0 ± 0.3 |
| Change at Week 8 | 0 ± 0.2 |
| Change at Week 12 | 0 ± 0.2 |
| Change at Week 16 | 0 ± 0.2 |
| Change at Week 20 | 0 ± 0.2 |
| Change at Week 24 | 0 ± 0.1 |
| Change at Week 32 | 0 ± 0.2 |
| Change at Week 40 | 0 ± 0.2 |
| Change at Week 52 | 0 ± 0.3 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | 0 ± 0.3 |
The SNAP-IV, ADHD Inattention subscale contains 19 items, items 1 to 9 measure inattention, items 11 to 19 measure hyperactivity/impulsivity, and item 10 for inattention domain that scores the intensity of each item during the last seven days on a 0 to 3 scale (0=not at all, 1=just a little, 2=pretty much, 3=very much). The lowest possible score is 0; highest is 57. The negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -0.1 ± 0.3 |
| Change at Week 8 | 0 ± 0.3 |
| Change at Week 12 | -0.1 ± 0.3 |
| Change at Week 16 | -0.1 ± 0.4 |
| Change at Week 20 | -0.1 ± 0.3 |
| Change at Week 24 | -0.2 ± 0.4 |
| Change at Week 32 | -0.2 ± 0.4 |
| Change at Week 40 | -0.2 ± 0.4 |
| Change at Week 52 | -0.1 ± 0.4 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -0.1 ± 0.4 |
The CY-BOCS is used to assess characteristics of obsession and compulsion for the week prior to the interview. Nineteen items are rated in the CY-BOCS, but the total score is the sum of only items 1 to 10 (excluding items 1b and 6b). The obsession and compulsion subtotals are the sums of items 1 to 5 (excluding 1b) and 6 to 10 (excluding 6b), respectively. A missing value for any CY-BOCS item scale could result in a missing total score or obsession and compulsion subtotals of which the item scale is a component. At baseline, the full CY-BOCS interview is conducted. At all post-baseline time points, the "Questions on Obsessions" (items 1 to 5) and "Questions on Compulsions" (items 6 to 10) are reviewed and the target symptoms identified at baseline are the primary focus for rating severity. CY-BOCS total score could range from 0 to 40. Higher scores indicate worse outcome. A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -0.2 ± 1.6 |
| Change at Week 8 | -0.2 ± 1.9 |
| Change at Week 12 | -0.3 ± 1.8 |
| Change at Week 16 | -0.4 ± 1.9 |
| Change at Week 20 | -0.4 ± 2 |
| Change at Week 24 | -0.5 ± 2.2 |
| Change at Week 32 | -0.6 ± 2.5 |
| Change at Week 40 | -0.6 ± 2.4 |
| Change at Week 52 | -0.3 ± 2.4 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -0.3 ± 2.4 |
The CDRS-R is composed of 17 interviewer-rated symptom areas: impaired schoolwork, difficulty having fun, social withdrawal, appetite disturbance, sleep disturbance, excessive fatigue, physical complaints, irritability, excessive guilt, low self-esteem, depressed feelings, morbid ideas, suicidal ideas, excessive weeping, depressed facial affect, listless speech, and hypoactivity. The CDRS-R total score is the sum of scores for the 17 symptom areas. A missing value for any CDRS-R item scale or a not rated item scale (indicated by the value of 0) could result in a missing total score. The CDRS-R total score is the sum of scores for the 17 symptom areas and could range from 17 to 113 with higher values indicating worse outcome. A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | 0 ± 2.3 |
| Change at Week 8 | 0 ± 2.6 |
| Change at Week 12 | -0.2 ± 3.1 |
| Change at Week 16 | -0.4 ± 2.9 |
| Change at Week 20 | -0.3 ± 3.1 |
| Change at Week 24 | -0.2 ± 2.5 |
| Change at Week 32 | -0.1 ± 2.8 |
| Change at Week 40 | -0.4 ± 2.7 |
| Change at Week 52 | -0.2 ± 3.3 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | 0.3 ± 4.1 |
The PARS has 2 sections: the symptom checklist and the severity items. The symptom checklist is used to determine the child's repertoire of symptoms during the past week. Information is elicited from the child and parent(s) and the rater then combines information from all informants using his/her best judgment. The 7-item severity list is used to determine severity of symptoms and the PARS total score. The time frame for the PARS rating is the past week. Only those symptoms endorsed for the past week are included in the symptom checklist and rated on the severity items. The PARS total severity score is the sum of items 2, 3, 5, 6, and 7. The total severity score ranges from 0 to 25, with 25 being the worst. Codes "8" (Not applicable) and "9" (Does not know) are not included in the summation (ie, equivalent to a score of 0 in the summation). A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -0.1 ± 2.6 |
| Change at Week 8 | -0.2 ± 2.4 |
| Change at Week 12 | -0.3 ± 1.8 |
| Change at Week 16 | -0.3 ± 2 |
| Change at Week 20 | -0.3 ± 2.1 |
| Change at Week 24 | -0.3 ± 2.3 |
| Change at Week 32 | -0.3 ± 2.4 |
| Change at Week 40 | -0.6 ± 2.3 |
| Change at Week 52 | -0.7 ± 2.4 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -0.3 ± 2.6 |
| kilogram | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 12 | 1.4 ± 2.3 |
| Change at Week 24 | 2.5 ± 3.9 |
| Change at Week 52 | 4.7 ± 6 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | 3.8 ± 5.1 |
Waist circumference was recorded before a participant's meal and at approximately the same time at each visit. Measurement was accomplished by locating the upper hip bone and the top of the right iliac crest and placing the measuring tape in a horizontal plane around the abdomen at the level of the crest. Before reading the tape measure, the assessor assured that the tape was snug, but did not compress the skin, and is parallel to the floor. The measurement was made at the end of a normal exhalation.
| centimeter | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 12 | 0.4 ± 3.9 |
| Change at Week 24 | 1 ± 5.2 |
| Change at Week 52 | 2.3 ± 6.8 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | 1.9 ± 5.8 |
The YGTSS is a semi-structured clinical interview designed to measure the tic severity. This scale consisted of a tic inventory, with 5 separate rating scales to rate the severity of symptoms, and an impairment ranking. Ratings were made along 5 different dimensions on a scale of 0 to 5 for motor and vocal tics, each including number, frequency, intensity, complexity, and interference. The YGTSS TTS was the summation of the severity scores of motor and vocal tics. The total tic score (TTS) ranged from 0 (none) to 50 (severe) with higher score represent more severe symptoms (A negative change from Baseline indicates improvement).
| score on scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -2.6 ± 5.4 |
| Change at Week 8 | -3.8 ± 5.6 |
| Change at Week 12 | -4.5 ± 6.7 |
| Change at Week 16 | -4.6 ± 6.8 |
| Change at Week 20 | -5.5 ± 7.2 |
| Change at Week 24 | -5.8 ± 7.9 |
| Change at Week 32 | -6 ± 9.1 |
| Change at Week 40 | -6.4 ± 9.3 |
| Change at Week 52 | -5.8 ± 8.8 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -5.9 ± 8.4 |
The severity of illness and efficacy of study medication for each participant were rated using the CGI-TS scale. The study physician rated the participants total improvement whether or not it is due to study treatment. All responses were compared to the participants condition at Baseline (Day 0). Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. A negative change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -0.2 ± 0.7 |
| Change at Week 8 | -0.4 ± 0.8 |
| Change at Week 12 | -0.4 ± 0.8 |
| Change at Week 16 | -0.5 ± 0.8 |
| Change at Week 20 | -0.6 ± 0.8 |
| Change at Week 24 | -0.5 ± 0.9 |
| Change at Week 32 | -0.6 ± 1 |
| Change at Week 40 | -0.7 ± 1.1 |
| Change at Week 52 | -0.7 ± 1.1 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -0.6 ± 1.1 |
The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100). A missing value of a YGTSS item scale could result in a missing Total YGTSS score. A negative change in Total YGTSS score from baseline represents an improvement in symptoms.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -5.6 ± 10.4 |
| Change at Week 8 | -7.4 ± 11.8 |
| Change at Week 12 | -8.6 ± 12.9 |
| Change at Week 16 | -9.4 ± 13.9 |
| Change at Week 20 | -10.7 ± 14.9 |
| Change at Week 24 | -10.4 ± 16 |
| Change at Week 32 | -11.6 ± 17.5 |
| Change at Week 40 | -12.6 ± 17.5 |
| Change at Week 52 | -10.8 ± 17.4 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -11.4 ± 16.7 |
Response rates - clinical response was defined as percentage of participants \>25% improvement from Baseline to endpoint in YGTSS TTS OR a CGI-TS change score of 1 \[very much improved\] or 2 \[much improved\] at endpoint. The YGTSS consists of a tic inventory, with 5 separate rating scales to rate the severity of symptoms (on a scale of 0 to 5 for 5 different dimensions, including number, frequency, intensity, complexity, and interference) of motor and vocal tics, and an impairment ranking. The Total YGTSS score is the summation of the severity scores of motor and vocal tics and also the ranking of impairment (range of 0 to 100) with higher score representing severe symptoms.
| percentage of participants | Aripiprazole (Once Weekly) |
|---|---|
| Week 4 | 66.2 |
| Week 8 | 69.7 |
| Week 12 | 72.6 |
| Week 16 | 72.3 |
| Week 20 | 74.2 |
| Week 24 | 71.8 |
| Week 32 | 77.8 |
| Week 40 | 80.8 |
| Week 52 | 76.5 |
| Last Visit (Week 52 or early termination Visit before Week 52) | 71.3 |
Treatment discontinuation rate was calculated as the percentage of participants who discontinued treatment.
| percentage of participants | Aripiprazole (Once Weekly) |
|---|---|
| All reasons | 47.6 |
| Other than sponsor discontinued study site | 22.4 |
The GTS-QOL is a disease-specific patient-reported scale for the measurement of health-related quality of life in participants with Tourette's Disorder, taking into account the complexity of the clinical picture of the disease. The questionnaire consists of a 27-item Tourette's Disorder-specific scale with 4 subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL total score ranged from 0 (extremely dissatisfied with life) and 100 (extremely satisfied with life). A positive change from Baseline indicates improvement.
| score on a scale | Aripiprazole (Once Weekly) |
|---|---|
| Change at Week 4 | -2.9 ± 8.2 |
| Change at Week 24 | -3.6 ± 11.3 |
| Change at Week 52 | -4.3 ± 10.5 |
| Change at Last Visit (Week 52 or early termination Visit before Week 52) | -3.8 ± 10.9 |
Collected over From first dose up to 4 weeks post last dose (Up to 56 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aripiprazole (Once Weekly) | 0/170 (0%) | 5/170 (2.9%) | 57/170 (33.5%) |
| Event | Aripiprazole (Once Weekly) |
|---|---|
| Blood creatinine phosphokinase increasedInvestigations | 1/170 |
| Blood lactate dehydrogenase increasedInvestigations | 1/170 |
| Alanine aminotransferase increasedInvestigations | 1/170 |
| Aspartate aminotransferase increasedInvestigations | 1/170 |
| Tourette's disorderCongenital, familial and genetic disorders | 1/170 |
| TremorNervous system disorders | 1/170 |
| Suicidal ideationPsychiatric disorders | 1/170 |
| Type 1 diabetes mellitusMetabolism and nutrition disorders | 1/170 |
| AppendicitisInfections and infestations | 1/170 |
| Event | Aripiprazole (Once Weekly) |
|---|---|
| HeadacheNervous system disorders | 19/170 |
| Weight increasedInvestigations | 14/170 |
| VomitingGastrointestinal disorders | 12/170 |
| NasopharyngitisInfections and infestations | 12/170 |
| Upper respiratory tract infectionInfections and infestations | 12/170 |
| SomnolenceNervous system disorders | 11/170 |
| NauseaGastrointestinal disorders | 10/170 |
The Enrolled Sample included participants who met the entrance criteria and assigned to the open label treatment (regardless of whether or not they were dosed with study drug).
| Age, Continuous(years) | Aripiprazole (Once Weekly) |
|---|---|
| Mean | 12.2 ± 2.9 |
| Sex: Female, Male(Participants) | Aripiprazole (Once Weekly) |
|---|---|
| Female | 45 |
| Male | 125 |
| Ethnicity (NIH/OMB)(Participants) | Aripiprazole (Once Weekly) |
|---|---|
| Hispanic or Latino | 31 |
| Not Hispanic or Latino | 136 |
| Unknown or Not Reported | 3 |
| Race (NIH/OMB)(Participants) | Aripiprazole (Once Weekly) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 36 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 13 |
| White | 117 |
| More than one race | 0 |
| Unknown or Not Reported | 3 |
| Region of Enrollment(participants) | Aripiprazole (Once Weekly) |
|---|---|
| Canada | 19 |
| South Korea | 15 |
| Romania | 8 |
| Hungary | 14 |
| United States | 50 |
| Taiwan | 21 |
| Ukraine | 21 |
| Mexico | 14 |
| Bulgaria | 5 |
| Germany | 3 |
| Weight(Kilogram) | Aripiprazole (Once Weekly) |
|---|---|
| Mean | 51.5 ± 19 |
| Height(centimeter) | Aripiprazole (Once Weekly) |
|---|---|
| Mean | 154.2 ± 16.4 |
| Body Mass Index (BMI)(Kilogram per meter square) | Aripiprazole (Once Weekly) |
|---|---|
| Mean | 21.0 ± 4.7 |
1 further baseline measures are reported on the registry.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/.
Data sharing details ↗ · clinical-trials.otsuka.com
No publications or documents are linked to this record.
Ran from Oct 2011 to primary completion in Mar 2014, 28 months.
Results were first posted in Oct 2021, 7 years 6 months after primary completion. A results delay was requested in Mar 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aripiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →